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Abstract
AIM
To evaluate the diagnostic and prognostic value of 
presepsin in cirrhosis associated bacterial infections. 
METHODS
Two hundred and sixteen patients with cirrhosis were 
enrolled. At admission, presence of bacterial infections 
and level of plasma presepsin, serum C-reactive protein 
(CRP) and procalcitonin (PCT) were evaluated. Patients 
were followed for three months to assess the possible 
association between presepsin level and short-term 
mortality. 
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i41.0000
1 November 7, 2016|Volume 22|Issue 41|WJG|www.wjgnet.com
World J Gastroenterol  2016 November 7; 22(41): 0000-0000
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
ORIGINAL ARTICLE
Presepsin teardown - pitfalls of biomarkers in the diagnosis 
and prognosis of bacterial infection in cirrhosis
Retrospective Study
Maria Papp, Tamas Tornai, Zsuzsanna Vitalis, Istvan Tornai, David Tornai, Tamas Dinya, Andrea Sumegi, 
Peter Antal-Szalmas
RESULTS
Present 34.7 of patients had bacterial infection. 
Presepsin levels were significantly higher in patients 
with infection than without (median, 1002 vs  477 
pg/mL, P  < 0.001), increasing with the severity of 
infection (organ failure [OF]Yes vs  No: 2358 vs  710 pg/
mL, P  < 0.001). Diagnostic accuracy of presepsin for 
severe infections was similar to PCT and superior to 
CRP (AUC-ROC: 0.85, 0.85 and 0.66, respectively, P  = 
NS for presepsin vs  PCT and P  < 0.01 for presepsin vs  
CRP). At the optimal cut-off value of presepsin > 1206 
pg/mL sensitivity, specificity, positive predictive values 
and negative predictive values were as follows: 87.5%, 
74.5%, 61.8% and 92.7%. The accuracy of presepsin, 
however, decreased in advanced stage of the disease 
or in the presence of renal failure, most probably 
because of the significantly elevated presepsin levels in 
non-infected patients. 28-d mortality rate was higher 
among patients with > 1277 pg/mL compared to those 
with ≤ 1277 pg/mL (46.9% vs  11.6%, P  < 0.001). In 
a binary logistic regression analysis, however, only PCT 
(OR = 1.81, 95%CI: 1.09-3.01, P  = 0.022) but neither 
presepsin and nor CRP were independent risk factor 
for 28-d mortality after adjusting with MELD score and 
leukocyte count.
CONCLUSION
Presepsin is a valuable new biomarker for defining 
severe infections in cirrhosis proving same efficacy as 
PCT. However, it is not a useful marker of short-term 
mortality. 
Key words: Presepsin; Cirrhosis; Bacterial infection; 
Organ failure; Mortality
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Core tip: C-reactive protein (CRP) and procalcitonin 
(PCT) are broadly used in clinical practice to aid 
early diagnosis of bacterial infections, but they have 
limitations in cirrhosis. Additional biomarkers with 
enhanced accuracy are highly needed. Presepsin is 
a novel biomarker of infection and sepsis, but has 
not been assessed in cirrhosis so far. In the present 
study we evaluated the diagnostic and prognostic 
performance of presepsin in cirrhosis-associated 
infections in comparison with classic acute phase 
proteins. Presepsin measurement enhanced diagnostic 
capacity of CRP and reflected the severity of infections 
more accurately, with a similar efficacy as PCT. 
Advanced diseases stage and renal failure limited the 
diagnostic accuracy. The increase in PCT level but 
not in presepsin concentration was an independent 
predictor of short-term mortality during infectious 
episodes.
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INTRODUCTION
Infectious episodes represent particularly important 
causes of progression of liver failure and the deve­
lopment of liver­related complications[1]. Due to altered 
sensitivity, the end­organ damaging effect of bacterial 
infection is greater in cirrhosis and often culminates 
in newly developed liver and/or extrahepatic organ 
failures, which is associated with a very high short­term 
mortality rate[2,3]. 
Early recognition of bacterial infections is essential, 
however, in the clinical practice their accurate 
identification is challenging from both the clinical[4] 
and the laboratory part[5]. In cirrhosis, usual clinical 
presentations lack up to 50% of the bacterial infections 
and are replaced by non­specific complaints or just 
revealed by organ dysfunctions. Due to some disease 
specific characteristics, there is an evident lack of 
sensitivity and specificity of the conventional laboratory 
and clinical parameters for the definition of systemic 
inflammatory response (SIRS)[6,7], which makes it 
difficult to diagnose sepsis. 
Currently C­reactive protein (CRP) and procalcitonin 
(PCT) are broadly used in the clinical practice to aid 
the early diagnosis of bacterial infection[8]. In cirrhosis, 
these conventional markers, however, perform 
somewhat differently in comparison with the non­
cirrhotic patient populations for various reasons. For 
the first, if the main source of the molecule is the liver, 
like in the case of CRP, synthesis of the molecule is 
affected by liver failure and its severity. As a result 
the diagnostic accuracy of liver synthesised acute 
phase proteins (APPs) decreases in advanced stage of 
cirrhosis[9]. Moreover, peak levels can be misleading 
and do not indicate the severity of the infection 
adequately, since the more severe the underlying 
liver dysfunction, the lower the CRP response to 
bacteraemia is[10]. Secondly, elimination of certain 
molecules can be affected by renal failure and also 
renal replacement therapy. Acute kidney injury (AKI) 
is frequent in patients with cirrhosis, especially in 
bacterial infections[11]. While CRP has a high molecular 
weight (MW) (115­kDa) and its renal clearance is 
negligible[12,13], PCT is small with a MW of 13 kDa and 
renal elimination is thought to be one of the major 
pathways for its elimination[14]. Accordingly, false or 
inappropriate increase of the PCT level was reported in 
end­stage renal disease patients due to the prolonged 
elimination rate[15,16]. Similarly, artificial reduction of 
the PCT level was also found after renal replacement 
therapy (HCO­CVVHDF). Proteins with MW < 60 
kDa is filtered by the dialysis membrane[17]. Thirdly, 
inflammatory state sustained by bacterial translocation 
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(BT) and without overt infection is sufficient alone to 
elevate inflammatory markers to a significant level[5,9]. 
Bacterial translocation is an increasing problem with 
diseases severity[18].
Accordingly, data are not homogeneous about the 
optimal cut­off for either of CRP and PCT to differentiate 
patients with infection from those without[19­23]. Probably 
using a single threshold is not appropriate. Additional 
biomarkers are highly needed to optimize the rule in 
and rule out processes necessary for the diagnosis 
and also for the severity assessment of the infectious 
episodes in cirrhosis.
Presepsin (soluble CD14 subtype, sCD14­ST) is 
a 13­kDa­cleavage product of CD14 receptor that 
recognizes different cell surface structure of both 
Gram­negative and positive bacteria. Presepsin in the 
circulation can be perceived as a witness of activated 
monocyte­macrophage in response to pathogens[24]. 
Several recent clinical studies have shown that 
presepsin is a specific and sensitive novel marker for 
the diagnosis of sepsis[25], for evaluating the severity 
of sepsis and for predicting the outcome[26,27]. Beyond 
sepsis, presepsin is worthy of studying in those clinical 
settings, where systemic infections are frequently 
associated with severe diseases course such in 
cirrhosis [acute decompensation (AD), organ failure]. 
Contributive role of presepsin for the diagnosis and 
prognosis of cirrhosis associated bacterial infection has 
not been assessed extensively so far. 
In the present study, we aimed to assess (1) 
performance of presepsin in the diagnosis of cirrhosis 
associated bacterial infections in comparison with 
routinely used APPs such as CRP and PCT; (2) whether 
presepsin is devoid of the limitations of classic APPs 
related to cirrhosis; and (3) whether presepsin is able 
to provide prognostic information during infectious 
episodes in cirrhosis.
MATERIALS AND METHODS
Patient population
Two hundred and sixteen, well­characterized patients 
with cirrhosis (male/female: 118/99, age: 57.5 ± 
10.3 years, disease duration: 3.9 ± 4.2 years) were 
included consecutively from our in­ and outpatient 
Gastroenterology Department between May 2010 and 
April 2011. The diagnosis of cirrhosis was considered 
either histologically proven or considered obvious by 
clinical, biochemical and morphological criteria[28]. 
Data collection
The clinical and laboratory characteristics of the patients 
are presented in Table 1. Clinical data were recorded 
at enrolment. These concerned demographics, co­
morbidities (including cardio­ and cerebrovascular, 
respiratory, renal disorders, diabetes and extrahepatic 
cancers), etiology of cirrhosis, history and severity of 
liver disease, presence of hepatocellular carcinoma 
(HCC), reason for AD, clinical status of patients, and 
also presence, type and location of bacterial infection. 
Severity of the cirrhosis was graded according to liver­
oriented scores [Child­Pugh score (CPs) and the model 
for end­stage liver disease (MELD)][29]. Episodes of AD 
were defined by acute development of large ascites, 
hepatic encephalopathy, gastrointestinal hemorrhage, 
bacterial infection or any combination of these warranting 
hospital admission[3]. The enrolled patients were followed 
for 90 d or until death. Presence and grade of organ 
system failure(s) [OF] were determined retrospectively 
based on the available clinical and laboratory data after 
accessibility of CLIF­C Organ Failure Score[30]. 
The diagnosis of bacterial infection was established 
by assessment of clinical symptoms and laboratory 
reports, including microbiological culture results (if 
available), compatible findings of imaging techniques, 
and the effect of antibiotic treatment by two 
independent gastroenterologists (M.P. and Zs.V.). 
Following bacterial infections were considered and 
diagnosed on the basis of conventional criteria: (1) skin 
and soft tissue infections[31]; (2) lower respiratory tract 
infections (acute bronchitis, pneumonia)[32]; (3) urinary 
tract infections (UTI) (cystitis, pyelonephritis)[33]; (4) 
some rare causes of infections, such as biliary tract 
infections (cholecystitis, cholangitis, liver abscess), 
osteomyelitis, and endocarditis; (5) spontaneous 
bacterial peritonitis (SBP), diagnosis of which was 
based on ascitic fluid polymorphonuclear cell (PMN) 
count exceeding 250/mm3
 
and3/or positive culture if 
secondary causes of peritonitis were excluded (EASL 
guidelines[34]); and (6) bacterial infection of unknown 
origin defined when clinical symptoms and signs of 
infection were present and confirmed by microbiological 
demonstration of the causative organism from blood 
culture in the absence of site-specific infection. Bacterial 
infection was considered severe when the infectious 
episode was complicated by OF.
Measurements of presepsin and other laboratory 
parameters
Venous blood samples were captured at enrolment. 
Routine laboratory data, such as liver biochemistry, 
renal function, blood count and serum CRP and PCT 
levels were determined directly at the Department 
of Laboratory Medicine. Methods for qualitative 
assessment of serum CRP and PCT levels were 
reported previously[9].
For presepsin measurements, blood samples were 
immediately centrifuged at 3000 g for 10 min, and 
plasma was stored at ­70 ℃ until use. Presepsin levels 
were measured by means of a PATHFAST® presepsin 
analyzer (Mitsubishi Chemical Medience Corporation, 
Tokyo, Japan) which is based on chemiluminescent 
enzyme immunoassay, with a detection limit of 20 
pg/mL. 
Outcome
For outcome assessment, a follow­up examination 
was set up at the 28th d after enrolment in the study. 
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negative predictive values (NPV) were calculated to 
determine the predictive power of individual APPs or 
their combinations in all the three clinical settings. 
Binary logistic regression was used to assess the 
relationship between APPs and short­term mortality 
adjusted for the MELD score and WBC count. For 
the analysis APPs were loge­transformed to ensure 
normal distribution. Associations are given as odds 
ratios (OR) or likelihood ratios (LR) with a 95%CI. A 
2­sided probability value < 0.05 was considered to 
be significant. For statistical analysis and graphical 
presentation SPSS 22.0 (SPSS Inc., Chicago, IL, United 
States) and GraphPad Prism 7 (San Diego, CA, United 
States) were used.
The statistical methods of this study were reviewed 
by Professor Elek Dinya, PhD, DSc, Semmelweis 
University, Institute of Health Informatics, Budapest, 
Hungary.
Review of the literature
We performed a systematic review of studies reporting 
on CRP and PCT in prognosis of cirrhosis. Papers were 
eligible if they presented original research in adult 
patients with cirrhosis and reported association of CRP 
and/ or PCT to the disease outcome either in patients 
with or without bacterial infection. Studies had to 
Patients who survived until follow­up were counted as 
survivors, whereas patients who died within the follow­
up period were counted as non­survivors. 
Statistical analysis
Variables were tested for normality using Shapiro 
Wilk’s W test. Continuous variables were summarized 
as mean ± SD or as medians [interquartile range (IQR)] 
according to their homogeneity. Categorical variables 
were compared with the χ 2 test or χ 2 test with Yates 
correction as appropriate. Continuous variables were 
compared with the Mann­Whitney U test or Student’s 
t test. Relationship between continuous variables was 
assessed with the non­parametric Spearman corre­
lation. Diagnostic accuracy of presepsin and other APPs 
for defining various study­endpoints: (1) presence of 
bacterial infection (2) presence of severe infection, and 
(3) short­term mortality was estimated using receiver 
operating curve (ROC) analysis by plotting sensitivity 
vs 1-specificity. Area under the curve (AUC-ROC) and 
corresponding 95%CI were calculated. ROC curves 
were compared with the method of DeLong et al[35] 
in Medcalc. Youden index was chosen, calculated as 
the maximum (sensitivity + specificity ­ 1) value, to 
estimate the best discriminate thresholds. Sensitivities, 
specificities, positive predictive values (PPV) and 
Table 1  Demographic, clinical and laboratory characteristics of patients with or without bacterial infections
Non-infected Infected P  value
n 141 75
Gender (male/female) 77/64 41/34 N.S
Age (yr) 57.3 ± 10.7 58.1 ± 9.7 N.S
Child-Pugh score 6.9 ± 1.7   9.3 ± 2.2 < 0.001
Child-Pugh stage, n (%)
   A 58 (41.1) 6 (8.0) < 0.001
   B 65 (46.1) 28 (37.3)
   C 18 (12.8) 41 (54.7)
MELD score 12.3 ± 4.1 19.1 ± 9.1 < 0.001
Serum bilirubin (μmol/L)   41.4 ± 38.3   124.1 ± 147.4 < 0.001
Serum albumin (g/L) 35.4 ± 7.1 28.1 ± 6.5 < 0.001
INR   1.3 ± 0.2   1.6 ± 0.5 < 0.001
Serum creatinine (μmol/L)   83.8 ± 74.3   131.2 ± 129.9 < 0.001
Ascites present, n (%) 58 (41.1) 59 (78.7) < 0.001
HCC, n (%) 4 (2.8) 11 (14.7)     0.003
Comorbidities present, n (%) 72 (51.1) 45 (60.0) NS
Type of bacterial infections, n (%)
   UTI 25 (29.4)
   SBP 20 (23.5)
   Pneumonia 18 (21.2)
   SSTI 4 (4.7)
   Miscellaneous 18 (21.2)
   Multiple   9 (10.6)
Acute phase proteins, median (IQR)
   Presepsin (pg/mL) Overall 477 (332-680) 1002 (575-2149) < 0.001
OF absent OF present 710 (533-1277) 2357 (1398-3666) < 0.001
   CRP (mg/L) Overall 4.6 (1.8-8.8) 30.1 (11.3-57.4) < 0.001
OF absent OF present 25 (9.6-40.5) 52.2 (23.4-84)     0.027
   PCT (μmol/L) Overall 0.1 (0.1-0.2) 0.4 (0.1-1.2) < 0.001
OF absent OF present 0.2 (0.1-0.5) 1.7 (0.6-5.3) < 0.001
Data are presented as mean ± SD or n (%) if not otherwise indicated. CRP: C-reactive protein; HCC: Hepatocellular carcinoma; IQR: Interquartile range; 
INR: International normalized ratio; MELD: Model for end-stage liver disease score; NS: Non-significant; PCT: Procalcitonin; SD: Standard deviation; UTI: 
Urinary tract infection; SBP: Spontaneous bacterial peritonitis; SSTI: Skin and soft tissue infection.
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have been published in peer­reviewed journals. We 
started searching PubMed using the following search 
terms: [“C­reactive protein” OR “procalcitonin”] AND 
“liver cirrhosis”. Limits were human and time ranging 
from 1991 until 2016 (1st June). Only article reported 
short or long­term outcome in cirrhosis were included. 
This search revealed 20 articles. In Table 2 we sum­
marizes the clinical significance of CRP and PCT in 
the prediction of disease course in cirrhosis based on 
findings in relevant literature.
Ethical permission
All patients were informed of the nature of the study 
and signed an informed consent form. The regional 
and national committee (DEOEC RKEB/IKEB 5306­9/ 
2011, 3885/2012/EKU [60/PI/2012]) for research 
ethics approved the study protocol. 
RESULTS
Study population 
Two hundred and sixteen patients with cirrhosis were 
enrolled in this cohort. The main characteristics of 
patients with or without infection are summarized 
in Table 1. There were 118 men with a mean age of 
57.6 ± 10.3 years. The median Child­Pugh and MELD 
score were 7 (95%CI: 6­9) and 13 (95%CI: 10­17), 
respectively. The main baseline characteristics were as 
follows: alcoholic liver disease in 159 patients (73.6%), 
HCC in 15 patients (6.9%) and renal impairment 
in 33 (15.3%) based on creatinine cut­off values ≥ 
133 μmol/L. One­hundred and seventeen patients 
(54.2%) had extrahepatic co­morbidities. Acute 
decompensation of the disease warranting hospital 
admission occurred in a total of 101 patients (46.8%) 
Table 2  Association of classic acute phase proteins with mortality in patients with cirrhosis 
Ref. Year Journal Population n Outcome Measure Value
C-reactive protein
   Reuken et al[72] 2013 Liver Int Ascites 108 90-d mortality AUC 0.69 (0.59-0.79), P = 0.001
   Moreno et al[69] 2013 Liver Int Non-septic   95 1-yr mortality AUC 0.71 (0.6-0.8), P < 0.001
   Mortensen et al[70] 2012 Eur J Gastroenterol 
Hepatol
Stable alcohol cirrhosis   45 Long term 
mortality (about 
6- yr)
HR1  
1.074 (1.001-1.153), P = 0.046
   Wiese et al[74] 2014 Liver Int Stable cirrhotic 193 1- yr survival HR 1.18, P = 0.0483
   Lim et al[68] 2014 Plos One SBP   75 30-d mortality AUC 0.64 (0.49-0.79), P = 0.076
HR ND, P = 0.064
   Schwabl et al[73] 2015 Liver Int SBP 168 30-d mortality HR1 1.067 (1.004-1.134), P = 0.037
   Ha et al[65] 2011 Korean J Intern 
Med
Bacteraemia 202 30-d mortality Difference Survivor vs non-survivor2
37.8 vs 34.3 mg/L, P = 0.721
   Cervoni et al[20] 2012 J Hepatol CPs > 7 148 180-d mortality AUC 0.63 (0.51-0.73), P = ND
HR1,4 2.73 (1.41-5.26), P = 0.003
   Di Martino et al[64] 2015 Liver Transplant CPs > 7 109 90-d mortality HR1,4 2.21 (1.03-4.76), P = 0.042
   Cervoni et al[63] 2016 Eur J Gastroenterol 
Hepatol
CPs > 7 583 90-d mortality HR1,4 1.69 (1.01-2.81), P = 0.046
   Park et al[71] 2015 J Korean Med Sci Alcoholic cirrhosis various 
reasons for admission
409 30-d mortality OR "CRP > 20 not independent 
predictor"
   Ximenes et al[75] 2016 Am J Emerg Med Hepatic decompensation 149 Inhospital 
mortality
OR OR: ND, P > 0.100
   Kwon et al[67] 2015 BMC Gastroenterol Acute decompensation 184 30 d survival OR OR: ND, P = 0.122
   Lazzarotto et al[19] 2013 Ann Hepatol Acute decompensation   64 90 d survival Difference Survivor vs non-survivor2
7 vs 41 mg/L, P = 0.026
   Kronenberger et al[66] 2012 BMC Med. Acute decompensation + 
outpatients
120 Overall survival 
(196 ± 165 d)
HR Univariate: 0.314 
(0.141-0.702) , P = 0.005
Multivariate: ND, P = 0.077
Procalcitonin
   Lin et al[80] 2015 J Crit Care Acute decompensation   96 Sepsis in-
hospital 
mortality
AUC 0.692
   Kotecha et al[79] 2013 Eur J Gastroenterol 
Hepatol
Cirrhosis + SIRS 100 In-hospital 
survival
OR1 0.949 (0.868-1.037), P = 0.249
   Connert et al[78] 2003 Z Gastroenterol Compensated + 
decompensated
100 60-d mortality Percent died < 0.58 vs ≥ 0.58:
 9.1% vs 46.7%, P < 0.001
   Al-Dorzi et al[76] 2014 Clin Lab Septic shock   45 28-d mortality Difference Low PCT vs high PCT: 
80% vs 77%, P = 0.61
   Berres et al[77] 2009 Liver Int Critically ill   38 ICU mortality Difference NA, P = NS
1Adjusted for MELD score; 2Median values; 3Not significant in the log-rank test; 4CRP variation over 15 d. SBP: Spontaneous bacterial peritonitis; HR: 
Hazard ratio; AUC: Area under the curve; OR: Odds ratio; CPs: Child-Pugh score; ICU: Intensive care unit; SIRS: Systemic inflammatory response 
syndrome.
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of whom 27 (26.7%) had at least one OF. 
Documented bacterial infection was present in 75 
(34.7%) patients of whom 9 (12.0%) suffered from 
multifocal episode. Bacteria were Gram­negative 
in 52.6% and Gram­positive in 47.4% of culture­
positive cases. No cases of invasive fungal infections 
were detected. The distribution of infections is shown 
in Table 1. The infected and the non­infected patient 
groups did not differ in gender, age, and presence of 
comorbidities. However, patients with infections had 
more advanced disease stage, as indicated by median 
values of Child­Pugh and MELD score and presence 
of ascites. Renal impairment (29.3% vs 7.8%, P < 
0.001) and occurrence of HCC (14.7% vs 2.8%, P = 
0.003) were more frequent in patients with infection 
as compared to those without as well. The occurrence 
of AD episodes and the development of OF were more 
common in the presence of infections (AD INF vs NON­INF: 
85.3% vs 26.2%, P < 0.001 and OF INF vs. NON­INF: 37.5% 
vs 8.1%, P = 0.001). 
Association between presepsin levels and bacterial 
infections
Presepsin values ranged from 142 to 5950 pg/mL 
(median [IQR], 576 pg/mL [376­972]) and were 
significantly higher in patients with infection as 
compared to those without (1002 pg/mL [575­2149] 
vs 477 [332­680] pg/mL, P < 0.001) (Figure 1). This 
association was also confirmed in the different disease 
severity subgroups according to Child­Pugh stage 
(Figure 2A) or the presence of ascites (Figure 2B). In 
the subgroup of patients with renal failure, presepsin 
levels were also different numerically between infected 
and non­infected patient groups however it did not 
reach statistically significance (P = 0.08) (Figure 2C). 
Further evaluating non-infected patients, a significant 
increase was observed in presepsin levels in case of 
more advanced disease stage and also in the presence 
of renal failure (P < 0.001 for both).
Presepsin level was positively correlated with classic 
markers of bacterial infections, such as CRP, PCT, and 
different WBC parameters, but also with renal and liver 
function tests (Table 3) and accordingly with liver liver­
oriented scores (CPs and MELD).
Considering the type of infectious episodes, pre­
sepsin level was not different according to the location 
or Gram specificity of the infection (data not shown). 
Patients with multifocal infections (10.6%) showed 
numerically higher presepsin levels than those with 
unifocal ones without reaching statistically significance 
[2470 pg/mL (729­2671) vs 983 pg/mL (560­1774), P 
= 0.065]. Nonetheless, presepsin level was associated 
with the severity of the infection. Twenty­four 
infections (32%) were complicated with at least one 
OF. Presepsin level was significantly higher in patients 
with OF as compared to those without [2358 pg/mL 
(1398­3666) vs 710 pg/mL (533­1277), P < 0.001] 
(Figure 1).
Accuracy of presepsin level in the diagnosis of bacterial 
infections compared to classic acute phase proteins
The diagnostic accuracy of presepsin for identifying 
patients with infection was established by ROC analysis 
and compared to CRP and PCT. Presepsin was similar 
predictor of bacterial infection in overall [AUC­ROC, 
95%CI: 0.79 (0.73­0.84)] vs PCT [0.77 (0.71­0.83), 
P = 0.668] but somewhat lower than CRP [0.86 
(0.80­0.90), P = 0.057] (Figure 3A). Combination of 
CRP with presepsin, however, increased the sensitivity 
and NPV, compared with CRP on its own, by 9 % 
and 4 % respectively. A similar trend was found with 
the combination of CRP and PCT (Table 4). On the 
contrary, the diagnostic accuracy of presepsin [AUC­
ROC 95%CI: 0.85 (0.74­0.92)] for identifying patients 
with infection complicated by OF was similar to PCT 
[0.85 (0.74­0.92)] and clearly superior to CRP [0.66 
(0.54­0.77), P = 0.994 for presepsin vs PCT, and P 
Figure 1  Presepsin levels in patients with cirrhosis according to presence 
or absence and severity of bacterial infections (n = 216). Median presepsin 
levels are significantly higher in patients with infection as compared to those 
without and associated to the severity of the infection. Lines denote median 
values, boxes represent 25th-75th percentiles and whiskers indicate the 5th-95th 
range. P values were calculated by Mann-Whitney U-test or Kruskal-Wallis 
H-test as appropriate. INF: Bacterial infection.
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Table 3  Correlations between presepsin and different laboratory 
parameters or liver-orientated scores 
Variable Spearman’s rho P  value
CRP  0.63 < 0.001
PCT  0.53 < 0.001
Leucocyte count  0.27 < 0.001
Serum creatinine  0.36 < 0.001
Serum bilirubin  0.28 < 0.001
Serum albumin -0.40 < 0.001
INR  0.15     0.032
CPs  0.42 < 0.001
MELD score  0.45 < 0.001
CRP: C-reactive protein; CPs: Child-Pugh score; INR: International 
normalized ratio; MELD score: Model for end-stage liver disease; PCT: 
Procalcitonin.Organ failure
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< 0.01 for both presepsin vs CRP and PCT vs CRP] 
(Figure 3B). The optimum diagnostic thresholds for 
each individual biomarker based on ROC analysis and 
their performances belonging to the cut­off points are 
shown in Table 4. 
Diagnostic accuracy of presepsin level according to the 
disease severity 
Diagnostic accuracy of presepsin for identifying pa­
tients with infection decreased in advanced stage of 
the disease and also in the presence of renal failure. 
Specificity and LR values of presepsin > 844 pg/mL 
were obviously lower in patients with Child B or C 
stage cirrhosis (74%; LR+: 2.28, LR­: 0.56) compared 
with those with Child A (96%; LR+: 15.6, LR­: 0.31), 
whereas the difference in sensitivity was somewhat 
less (70% vs 58%). A similar trend was found when 
the performance of presepsin > 844 pg/mL was 
evaluated in patients with or without renal failure 
(specificity: 46% vs 87%; sensitivity: 86% vs 49%; 
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Figure 2  Presepsin levels in subgroups of patients with different diseases 
severity according to presence or absence of bacterial infections (n = 216). 
Significant differences in median presepsin levels between non-infected and 
infected patients are observed in all disease severity subgroups according to Child-
Pugh stage (A) or the presence of ascites (B). However, no significant difference is 
observed in renal failure subgroup (C). Among non-infected patients, a significant 
increase in median presepsin levels is observed according to disease severity or 
in the presence of renal failure. Lines denote median values, boxes represent 25th-
75th percentiles and whiskers indicate the 5th-95th range. P values were calculated 
by the Mann-Whitney U or the Kruskal-Wallis H-test as appropriate. Creatinine 
values of 4 patients were missing in the non-infected group.
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Figure 3  Receiver-operating characteristic curves of presepsin, procal-
citonin and C-reactive protein for the identification of bacterial infection 
overall (A) or bacterial infection complicated by organ failure (B). ROC 
analysis were performed (A) in the whole cohort (n = 216) or (B) in patients with 
bacterial infection (n = 75). The control group comprised (A) patients without 
bacterial infection (n = 141), or (B) patients with bacterial infection without organ 
failure (n = 51). AUC: Area under curve; CI: Confidence interval; CRP: C-reactive 
protein; PCT: Procalcitonin.
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LR+: 1.58 vs 3.86, LR­: 0.30 vs 0.58, respectively). 
Association of presepsin level with short-term mortality 
during infectious episodes
Seventy­five patients with bacterial infection were 
eligible for evaluation of short­term mortality. Twenty­
three patients (31.5%) died within 3 mo of follow­up. 
Of these, 20 patients (27.4%) died within the first 28 d. 
Plasma presepsin levels at admission were significantly 
higher in non­survivors than in survivors at the 28­d 
follow­up [2323 (1172­3688) vs 852 (549­1451) 
pg/mL, P < 0.001]. Discriminative ability (AUC­ROC) 
of presepsin was 0.76 with the best cut­off value of 
1277 pg/mL. 28­d mortality rate was significantly 
higher among patients with presepsin level above 
this threshold (46.9% vs 11.6%, P < 0.001). The 
optimum cut­off values and the belonging sensitivities, 
specificities, PPVs and NPVs of all three APPs for 
identifying non­survivors are summarized in Table 5. 
In the univariate logistic regression analysis, 
increased presepsin level was found to be a risk factor 
of short­term mortality during bacterial infection [OR = 
3.59 (95%CI: 1.65­7.84), P = 0.001] similarly to CRP 
and PCT. Presepsin level however lost it significance 
after adjusting for MELD score and leukocyte count 
[OR = 1.61, (95%CI: 0.65­3.97), P = 0.303], with 
multivariate binary logistic regression analysis. PCT 
was the only APP that was independently associated 
with the risk of short­term mortality [OR = 1.81, 
(95%CI: 1.09­3.01), P = 0.022] in this model (Table 6).
Table 4  Performance characteristics of presepsin and other acute phase proteins during bacterial infections in patients with cirrhosis 
in various clinical settings
Variable Cut-off values Sensitivity Specificity PPV NPV LR+ LR-
INF overall Presepsin (pg/mL) 844 60.0% 84.45 67.2% 79.9% 3.85 0.47
PCT (μmol/L) 0.39 53.3% 93.65 81.6% 79.0% 8.36 0.50
CRP (mg/L) 10.8 78.7% 84.4% 78.2% 88.1% 5.04 0.25
At least one marker positive 
(Presepsin/CRP)
88.0% 74.5% 64.7% 92.1% 3.45 0.16
At least one marker positive 
(PCT/CRP)
81.3% 84.2% 69.3% 91.1% 5.15 0.22
INF + OF Presepsin (pg/mL) 1206 87.5% 74.5% 61.8% 92.75 3.43 0.17
PCT (μmol/L)   0.5 79.2% 76.5% 61.3% 88.6% 3.36 0.27
CRP (mg/L) 40.5 62.5% 76.5% 55.6% 81.2% 2.66 0.49
PPV: Positive predictive value; NPV: Negative predictive value; LR+: Positive likelihood ratio; LR-: Negative likelihood ratio; PCT: Procalcitonin; CRP: 
C-reactive protein; MELD: Model for end-stage liver disease; INF: Infection; OF: Organ failure.
Table 5  Performance characteristics of presepsin, procalcitonin and C-reactive protein for prediction of short-term (28-d) mortality 
in patients with bacterial infection (n  = 75)
Variable Cut-off values AUC-ROC (95%CI) Sensitivity Specificity PPV NPV LR+ LR-
Presepsin (pg/mL) 1277 0.76 (0.64-0.85) 75.0% 69.1% 46.9% 88.4% 2.43 0.36
PCT (μmol/L) 0.48 0.87 (0.77-0.93) 90.0% 74.6% 56.2% 95.3% 3.54 0.13
CRP (mg/L) 39.6 0.74 (0.63-0.84) 75.0% 74.6% 51.7% 89.1% 2.95 0.34
PPV: Positive predictive value; NPV: Negative predictive value; LR+: Positive likelihood ratio; LR-: Negative likelihood ratio; PCT: Procalcitonin; CRP: 
C-reactive protein; MELD: Model for end-stage liver disease.
Table 6  Association of presepsin, procalcitonin and C-reactive protein levels with short-term (28-d) mortality in patients with 
cirrhosis and bacterial infection
Binary logistic regression analysis
Univariate Multivariate
Unadjusted P  value Adjusted for 
MELD
P value Adjusted for 
leucocyte count
P  value Adjusted for 
MELD and 
leucocyte count
P  value
ln(Presepsin) 3.59 (1.65-7.84)    0.001 1.9 (0.81-4.43) 0.138 2.91 (1.28-6.64) 0.011 1.61 (0.65-3.97) 0.303
ln(PCT) 2.54 (1.55-4.16) < 0.001 1.89 (1.14-3.14) 0.014 2.33 (1.42-3.83) 0.001 1.81 (1.09-3.01) 0.022
ln(CRP) 2.17 (1.23-3.81)    0.007 1.73 (0.93-3.21) 0.081 1.84 (1.03-3.31) 0.040 1.56 (0.81-2.99) 0.180
Associations are expressed as odds ratios and 95%CI per 1 loge-unit increase. MELD: Model for end-stage liver disease; PCT: Procalcitonin; CRP: C-reactive 
protein. 
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DISCUSSION
Infected patients with cirrhosis can be asymptomatic 
at initial stages, but highly susceptible to dissemination 
of infections due to their immunocompromised state 
that leads to development of severe disease specific 
complications with significant mortality rate[36,37]. 
Accurate laboratory markers are of importance to 
maximize the efficacy of diagnostic procedure of 
bacterial infections and thus making possible early 
intervention. C­reactive protein is the most widely 
used APP in the everyday clinical practice; however, it 
has some limitations in patients with cirrhosis[5]. Thus 
identification of novel biomarkers is required to reach 
this unmet need in this patient group.
Primary aim of our study was to assess the 
performance of presepsin ­ a recently reported novel 
sepsis marker ­ in the diagnosis of cirrhosis associated 
bacterial infections in comparison with routinely 
used APPs (CRP, PCT) in such a patient cohort that 
represents the everyday clinical practice. To the best 
of our knowledge, this is the first study in cirrhosis, 
reporting the feasibility and the usefulness of presepsin 
in these clinical settings. We evaluated a large cohort 
of patients, in which not only severe but also mild 
forms of the infections were represented. One­third 
of patients had mild infections and mainly localized to 
the urinary tract, while another subgroup of patients 
(32%) suffered in severe infectious episodes. In our 
study severe infectious episodes were defined by the 
presence of hepatic and/or extrahepatic OF(s), since 
currently accepted clinical definition of SIRS and hence 
sepsis[38] is not entirely applicable to cirrhotic patients 
for various reasons[5]. New definition of OFs has 
directly been elaborated for cirrhotic patient population 
recently[3,30] that use simple measures and is easy to 
apply in everyday clinical practice. Moreover presence 
of OF is predictive of worse outcome[2]. 
For the diagnosis of bacterial infections, the best 
cut­off level of presepsin was 844 pg/mL in our 
cirrhotic patient cohort. Diagnostic cut­off levels 
were different in previous studies in non­cirrhotic 
populations, but most reports suggest an approximate 
level of 400­600 pg/mL[39,40]. 
Presepsin alone was not suitable as a screening 
tool to search for infection, however adding it to 
CRP, we found that presepsin was clinically useful. 
For the first, this combination amended efficacy of 
identification of the infectious episode. Sensitivity and 
NPV were increased by 9% and 4% compared to CRP 
alone. Secondly, presepsin was able to distinguish 
severe infectious episode from non­severe ones 
more properly compared to CRP; AUC­ROC values 
were 0.85 and 0.66, respectively. Performance of 
presepsin corresponds to those reported in non­
cirrhotic septic patient populations. In a recent meta­
analysis of Zheng et al[41], comprising a total of 8 
studies and 1757 patients, the AUC of the summary 
ROC (SROC) was 0.82. In contrast, weak predictive 
power of CRP with an AUC­ROC of 0.64 was reported 
for the infections in critically ill patients with cirrhosis in 
intensive care unit (ICU)[22], which is also in agreement 
with our results. Regarding CRP, patients with cirrhosis 
may present reduced CRP in response to infection[5,10]. 
It is acknowledged, that level of certain APPs 
are different according to the pathogens causing 
infections, while others are not. In a landmark study 
of Angeletti et al[42] level of PCT and mid­regional 
pro­adrenomedullin (MR­proADM) were found to be 
significantly higher in patients with sepsis caused by 
Gram­negative than Gram­positive strains. These data 
are also confirmed by other studies[43­45]. Some reports 
also highlighted differences in circulating cytokine 
levels in bloodstream infections according to Gram 
specificity, i.e., Gram­negative infections leaded to 
higher increase in the level of interleukin (IL)­6, TNF­
alpha or IL­10[46]. On the contrary, levels of other APPs, 
such as C­reactive protein, soluble (s)CD14, sCD163 
or soluble urokinase plasminogen activator receptor 
(SuPAR) are not in relation with the Gram specificity 
of the infection[47­50]. In the present study, presepsin 
level was not different according to Gram specificity 
of the infection, which is in agreement with previous 
literature findings[51­53].
Overall, presepsin was indisputably a valuable 
complementary tool in our cirrhotic patient cohort 
from a clinical point­of­view, but cost issues might 
compromise their joint use in the laboratory screening 
procedure of infections. Adding presepsin to CRP 
increased significantly the cost, from 0.9 to 12.5 $. 
Medico­economic evaluation, however is lacking by 
this time and should be performed before proposing 
introduction of their combined use into routine clinical 
practice. Presepsin had very similar discriminative 
ability as PCT in both above­mentioned clinical 
settings. Furthermore, prices of presepsin and PCT are 
also comparable (12.5 and 10.7 $) suggesting their 
interchangeability in this patient population. 
Secondary aim of our study was to evaluate 
whether presepsin is devoid of the limitations of 
classic APPs in cirrhosis. Previously in a small case­
control study of Park et al[10] showed that the more 
severe the underlying liver dysfunction, the lower the 
CRP response to bacteremia was. Equally in a former 
study[9] we reported that the diagnostic accuracy 
of both CRP and PCT for identifying patients with 
infection obviously decreased in advanced stage of 
the disease or in presence of ascites. Correspondingly, 
presepsin behaved alike in the present study. 
Presepsin is not primarily synthesized in the liver, thus 
not the decreasing synthetic capacity is the major 
limitation of their diagnostic performance in advanced 
cirrhosis. Ongoing chronic inflammatory state is a 
characteristic feature of cirrhosis that is potentially 
able to induce the synthesis of APPs in the absence of 
infection[54,55] and inevitably limits their clinical utility 
in the diagnostic procedure of bacterial infections. Out 
of various explanations, BT has major importance. 
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Bacterial translocation is frequently reported in patients 
with cirrhosis­associated severe liver dysfunction or 
ascites[56,57]. It is likely that this process resulted in 
higher presepsin level in our non­infected cirrhotic 
patients compared to healthy controls in previous 
studies[39,58]. Furthermore, presepsin levels were asso­
ciated with diseases severity (Child A: 361, Child B: 
530 and Child C: 703 pg/mL, P < 0.001) or presence of 
ascites (Yes vs No: 382 and 575 pg/mL, P < 0.001) in 
the non­infected patient group as well.
Another important, but rarely considered issue 
is the effect of renal function on the levels of APPs. 
Acute kidney injury (AKI) is a frequent complication 
of cirrhosis, occurring in up to 50% of hospitalized 
patients with cirrhosis[59]. Exact clearance mechanism 
of presepsin is unknown but considering its low MW it is 
presumably filtered by the glomeruli, reabsorbed, and 
catabolized within the proximal tubular cells[60]. From 
a clinical point of view, little information is available on 
the accurate association between presepsin level and 
kidney function. Nagata et al[61] reported that presepsin 
levels tend to increase with decreasing glomerular 
filtration rate ­ assessed by inulin renal clearance 
measurements ­ and are markedly high in patients 
with chronic renal failure or receiving hemodialysis. 
Nakamura et al[62] retrospectively analyzed presepsin 
levels in patients with or without sepsis presenting 
in the ICU, and found that presepsin levels were 
markedly high in patients with renal failure and end­
stage kidney disease. Accordingly, we evaluated 
the impact of kidney function on presepsin levels. 
Significant correlation was found between presepsin 
and serum creatinine level (Spearman’s rho: +0.36, P 
< 0.001). Furthermore, in a small subgroup of patients 
with renal failure, presepsin values were markedly high 
even in the absence of infection, at comparable levels 
to those of bacterial infection but without renal failure 
(1011 vs 774 pg/mL). These results suggest that the 
evaluation of presepsin levels in cirrhosis warrants 
special consideration during AD episodes complicated 
by AKI, and probably a different cut­off is needed for 
diagnosing infection in such patients.
Third aim of our study was to assess whether 
presepsin is able to provide prognostic information 
in cirrhosis associated bacterial infections. Studies in 
this clinical setting only exist regarding CRP[19,20,63­75] 
and PCT[76­80] and their findings are not without co­
ntroversies. In Table 2 we summarized available data 
on clinical significance of CRP and PCT in short or long-
term mortality of patients with cirrhosis. Most of the 
studies included both stable outpatients and patients 
with ongoing AD episodes with or without bacterial 
infections. Furthermore, evaluations often were done 
as a whole of these non­homogenous patient groups 
rendering direct comparison and single conclusion 
rather difficult. Recently, an important concept has 
been derived from the CANONIC study[3]. Acute­on­
chronic liver failure (ACLF) is associated with systemic 
inflammation and robust inflammatory response 
as judged by presence of elevated CRP or elevated 
leukocyte count results in worse outcome. Higher 
leukocyte count was found to be an independent 
predictor of 28­d transplant­free mortality. Based on 
these it was reasonable to assume that excessive 
increase in the APP levels, as a representative of the 
exaggerated inflammatory process could be associated 
with higher risk of short­term mortality in cirrhosis 
during bacterial infections. In patients with increased 
level of PCT, CRP and presepsin, short­term mortality 
was significantly higher. Indeed, higher level of PCT, 
CRP and presepsin were associated with short­term 
mortality in our study. However, after adjusting for 
diseases severity and leukocyte count, this association 
was only preserved for PCT and not for CRP or 
presepsin. From biological point of view this finding 
might be explained by the fact that presepsin has a 
different profile. It belongs to a distinctive class of 
molecules, so­called “hormonkines”[81]. Procalcitonin 
has a cytokine-like behaviour during inflammation and 
infection. It is produced primarily in neuroendocrine 
cells of various organs and represents involvement of 
several instead of one organ into the pro-inflammatory 
response[82]. Lastly, it has been demonstrated that 
PCT has various toxic effects and pose harm to the 
host. Administration of PCT to septic animals greatly 
increases mortality. Antibodies directed against PCT 
are able to ameliorate harmful effects of PCT with 
a marked decrease symptomatology and mortality 
of sepsis[83]. Presepsin represents activation of the 
monocyte­macrophage system during inflammatory 
process. Macrophages have a dual effect: production of 
excessive amount of inflammatory cytokines can cause 
tissue damage but involvement in the resolution of the 
inflammation promote tissue repair. This latter process 
is driven by M2­type macrophages in the presence of 
local microenvironmental anti­inflammatory signals 
such as IL­10[84].
Plasma presepsin was only assessed at enrolment, 
and thus dynamic changes of the concentration were 
unknown, which is inevitably one of the limitations 
of the present study. For this reason, clinical study 
will be needed to further investigate serial changes 
in presepsin levels and their possible association with 
worse outcome during infection. 
To conclude, the present study suggests that 
presepsin is a promising biomarker during diagnostic 
procedure of bacterial infections in cirrhosis for 
enhancing diagnostic capacity of CRP and reflecting 
more accurately the severity of infections. Performance 
of presepsin is equal to PCT in these clinical settings. 
Diagnostic accuracy of presepsin, however, decreases 
in advanced stage of the disease or in the presence of 
renal failure. Level of presepsin is not associated with 
the pathogens causing infections. Procalcitonin but 
not presepsin is a biomarker for predicting infection­
related short­term mortality in patients with cirrhosis.
COMMENTS
Background
Bacterial infections are frequent complications in cirrhosis and often culminate 
in newly developed liver and/or extrahepatic organ failures, which is associated 
with significant mortality. Early laboratory diagnosis of these episodes is 
essential but challenging. There is an evident lack of sensitivity and specificity 
of the conventional laboratory markers due to disease specific characteristics. 
Advanced stage of cirrhosis affects diagnostic accuracy of liver synthesised 
acute phase proteins (e.g., C-reactive protein) whereas acute kidney injury 
affects renal clearance of small molecules (e.g., procalcitonin). Enhanced 
bacterial translocation induces significant elevation of inflammatory markers 
as well. Additional biomarkers are highly needed to optimize the diagnostic 
procedure and severity assessment of the infectious episodes in cirrhosis. 
Presepsin is a novel biomarker of activated monocyte-macrophage in response 
to pathogens and specific and sensitive marker of the sepsis. 
Research frontiers
Presepsin is worthy of studying in cirrhosis, where systemic infections are 
frequently associated with severe diseases course, such as acute development 
of liver and/or extrahepatic organ failures. Contributive role of presepsin for the 
diagnosis and prognosis of cirrhosis associated bacterial infection, however, 
has not been assessed extensively so far. 
Innovations and breakthroughs
To our knowledge, this is the first study in cirrhosis to investigate the 
performance of presepsin in the diagnosis and prognosis of cirrhosis 
associated bacterial infections. Presepsin is a promising biomarker of infection 
in terms of diagnostic but not the prognostic procedure. Presepsin enhances 
diagnostic capacity of C-reactive protein and reflects more accurately severity 
of infections. In these clinical settings its performance is equal to procalcitonin. 
Diagnostic accuracy of presepsin, however, decreases in advanced stage of the 
disease or in the presence of renal failure. Level of presepsin is not associated 
to the pathogens causing infections. A clear strength of our study is the large 
study population that represents the everyday clinical practice and assessment 
of presepsin in comparison with routinely used acute phase proteins. We also 
provide a profound overview about the significance of routinely used acute 
phase proteins in the prognosis of cirrhosis.
Applications
In every day clinical practice, presepsin is a useful complementary adjunct to 
C-reactive protein and promising alternate of procalcitonin during the diagnostic 
procedure of cirrhosis associated bacterial infection. However, it is not devoid 
of the limitations of these classic acute phase proteins in the presence 
of advanced stage or certain acute complications of the disease. Larger 
prospective studies including serial changes in presepsin levels are needed 
to further investigate any possible association of presepsin level with worse 
outcome during infection or any suggestion for more aggressive or pre-emptive 
antibiotic therapy according to presepsin level.
Terminology
Presepsin or soluble CD14 subtype (sCD14-ST) is a 13-kDa-cleavage 
product of CD14 receptor of monocyte-macrophage that recognizes different 
cell surface structure of both Gram-negative and positive bacteria. Bacterial 
translocation is defined as an enhanced passage of bacteria and/or bacterial 
products from the intestinal tract to systemic circulation. 
Peer-review
This study suggests for the first time that presepsin is a promising biomarker 
during diagnostic procedure of bacterial infections in cirrhosis for enhancing 
diagnostic capacity of C-reactive protein and reflecting more accurately the 
severity of infections. Performance of presepsin is equal to procalcitonin 
in these clinical settings. Distinctly to procalcitonin and certain cytokines, 
presepsin level is not associated to the pathogens causing infections. 
Moreover, procalcitonin but not presepsin is a biomarker for predicting infection-
related short-term mortality in patients with cirrhosis. Acute phase proteins 
are not simply surrogate markers of on-going inflammatory processes of the 
host organism but might also be active participants, hence exerting harmful or 
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beneficial effects.
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